Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- ViiV’s HIV Drug Juluca Now Available in Japan
December 21, 2018
- Kowa Reps Continue Heavy GP Pitch for Parmodia in September: Anterio
December 21, 2018
- Taisho to Develop Overseas Biz in Asia and Europe through BMS’s Consumer Unit Buyout
December 21, 2018
- Fujifilm to Set Up New iPS Cell Production Facility in US, Start Operations in FY2019
December 21, 2018
- Life Science Institute Initiates Exploratory Clinical Trial of Muse Cell Product for Epidermolysis Bullosa
December 21, 2018
- Taisho to Acquire Bristol-Myers’s Consumer Health Unit
December 20, 2018
- Chugai’s Satralizumab Wins FDA Breakthrough Therapy Status
December 20, 2018
- ROS1/TRK Inhibitor Entrectinib Filed in Japan: Chugai
December 20, 2018
- Toray Sues Sawai, Fuso over Use Patent for Remitch OD Tablets
December 20, 2018
- Shionogi Licenses Cognitive Disorders Treatment Candidate from Tetra
December 20, 2018
- Shonan iPark Sets Up Consortium for Commercializing Disease Prevention
December 20, 2018
- Otezla Reduces Oral Ulcers in Japanese Behcet’s Disease Patients in PIII Study: Celgene
December 20, 2018
- Takeda Likely to Make NYSE Debut on Christmas Eve
December 19, 2018
- Bristol-Myers, Eisai Unit Ink I/O Collaboration
December 19, 2018
- Daiichi Sankyo Grants ROS1/NTRK Inhibitor Rights to AnHeart
December 19, 2018
- Shionogi Earns CHMP OK for Naldemedine
December 19, 2018
- Novo Links with H2 Inc. for Diabetes Treatment App
December 19, 2018
- Takeda, Alphabet's Health Unit Team Up on Japanese Parkinson’s Patient Research
December 19, 2018
- Adcetris Label Expansion Gets European Panel Nod: Takeda
December 18, 2018
- Hisamitsu Files Asenapine Transdermal Patch for Schizophrenia in US
December 18, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…